(...)... The deal covers the exclusive development and commercialisation rights for all oncology indications in China for PAT-SC1. Patrys will receive an upfront payment at that time and retains the right to develop and commercialise PAT-SC1 outside of China...(...)
on the other hand if you read that bit from Patrys website it says ALL oncology indications...so it may be leukemia? PAT-SC1 was for Gastric cancer and we had outstanding results (pure magic just about or miracle) and that is why I bought into it and loaded heaps (well, heaps for me).....lol...
wish they would hurry up with it...
- Forums
- ASX - By Stock
- PAB
- Ann: Appendix 4C - Quarterly - 30 September 2017
Ann: Appendix 4C - Quarterly - 30 September 2017, page-15
Featured News
Add PAB (ASX) to my watchlist
|
|||||
Last
0.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $14.40M |
Open | High | Low | Value | Volume |
0.7¢ | 0.7¢ | 0.7¢ | $20 | 2.803K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
27 | 5809153 | 0.6¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.7¢ | 2352672 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
27 | 5809153 | 0.006 |
16 | 7030776 | 0.005 |
7 | 4425000 | 0.004 |
5 | 2730016 | 0.003 |
2 | 4520000 | 0.002 |
Price($) | Vol. | No. |
---|---|---|
0.007 | 2352672 | 4 |
0.008 | 2057547 | 3 |
0.009 | 133332 | 1 |
0.010 | 1592000 | 4 |
0.011 | 1080000 | 2 |
Last trade - 13.08pm 12/07/2024 (20 minute delay) ? |
Featured News
PAB (ASX) Chart |